{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:03:00Z","timestamp":1787065380216,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Quzhou Municipal Science and Technology Project","award":["2024K120"],"award-info":[{"award-number":["2024K120"]}]},{"name":"Quzhou Municipal Science and Technology Project","award":["2024K121"],"award-info":[{"award-number":["2024K121"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:p>\n                    The present study aims to evaluate metformin-associated lactic acidosis (MALA) using real-world data from the Food and Drug Administration Adverse Event Reporting System (FAERS), providing reference for rational metformin use in clinical practice. Relevant adverse event data from January 2018 to March 2024 was extracted from the FAERS database. Disproportionality analysis, logistic regression, and time-to-event analysis were performed to assess risk factors, temporal patterns, and potential drug interactions associated with MALA. Among 40,883 metformin-related adverse event reports, 10,370 were MALA cases. Diabetes (adjusted odds ratio [OR]: 2.35, 95% confidence interval [CI]: 2.03\u20132.74), heart disease (adjusted OR: 1.75, 95% CI: 1.44\u20132.14), and hypertension (adjusted OR: 1.40, 95% CI: 1.21\u20131.62) were identified as significant risk factors. Contrast media showed the highest signal strength for drug interactions (reporting odds ratio\u2005=\u2005323.7, 95% CI: 226.8\u2013461.99), followed by furosemide and bisoprolol. The median time to lactic acidosis onset was 106 days, significantly longer than the 20 days for other adverse events (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.0001), with 44.0% occurring within 30 days and 40.4% after 360 days of therapy initiation. Taken together, our comprehensive analysis of the FAERS database enhances understanding of MALA risk factors and temporal patterns, contributing to informed decision-making in metformin\u2019s clinical application and facilitating timely management of this potentially life-threatening complication, particularly in patients with cardiovascular comorbidities.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045007","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:05:17Z","timestamp":1759781117000},"page":"e45007","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive analysis of metformin-associated lactic acidosis: Insights from the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1097","volume":"104","author":[{"given":"Jie","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Ninghai First Hospital, Ninghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wukun","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Ninghai First Hospital, Ninghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Third Hospital of Quzhou, Quzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Third Hospital of Quzhou, Quzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5494-8823","authenticated-orcid":false,"given":"Shuangli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Science and Education, The Third Hospital of Quzhou, Quzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260526","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tem.2024.07.017","article-title":"The direct targets of metformin in diabetes and beyond.","volume":"36","author":"Yao","year":"2025","journal-title":"Trends Endocrinol Metab"},{"key":"R2-20260526","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/SLA.0000000000006437","article-title":"Metformin preconditioning augments cardiac perfusion and performance in a large animal model of chronic coronary artery disease.","volume":"280","author":"Stone","year":"2024","journal-title":"Ann Surg"},{"key":"R3-20260526","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/dom.12974","article-title":"Metformin-associated lactic acidosis (MALA): Moving towards a new paradigm.","volume":"19","author":"Lalau","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R4-20260526","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: Current perspectives on causes and risk.","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"key":"R5-20260526","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2337\/dc15-2534","article-title":"Should restrictions be relaxed for metformin use in chronic kidney disease? Yes, they should be relaxed! What\u2019s the fuss?","volume":"39","author":"Bakris","year":"2016","journal-title":"Diabetes Care"},{"key":"R6-20260526","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.","volume":"2010","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R7-20260526","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review.","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"key":"R8-20260526","first-page":"e935730","article-title":"Transient complete blindness due to Metformin-Associated Lactic Acidosis (MALA) reversed with hemodialysis.","volume":"23","author":"Prada","year":"2022","journal-title":"Am J Case Rep"},{"key":"R9-20260526","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20140620","article-title":"Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria.","volume":"462","author":"Bridges","year":"2014","journal-title":"Biochem J"},{"key":"R10-20260526","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2049-3002-2-12","article-title":"Metformin directly acts on mitochondria to alter cellular bioenergetics.","volume":"2","author":"Andrzejewski","year":"2014","journal-title":"Cancer Metab"},{"key":"R11-20260526","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00592-016-0836-2","article-title":"Dose-related effects of metformin on acid-base balance and renal function in patients with diabetes who develop acute renal failure: a cross-sectional study.","volume":"53","author":"Cucchiari","year":"2016","journal-title":"Acta Diabetol"},{"key":"R12-20260526","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(15)00123-0","article-title":"Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study.","volume":"3","author":"Hung","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R13-20260526","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA adverse event reporting system database.","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Med"},{"key":"R14-20260526","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2024.07.1456","article-title":"Evaluation of anticancer therapy-related dermatologic adverse events: insights from food and drug administration\u2019s adverse event reporting system dataset.","volume":"91","author":"Salah","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"R15-20260526","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.jhep.2024.10.030","article-title":"Real-world evidence supporting the consensus-driven DILI control compounds list: an analysis of FAERS data.","volume":"82","author":"Ge","year":"2025","journal-title":"J Hepatol"},{"key":"R16-20260526","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s003300050746","article-title":"Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. ESUR contrast media safety committee.","volume":"9","author":"Thomsen","year":"1999","journal-title":"Eur Radiol"},{"key":"R17-20260526","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"R18-20260526","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib.","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R19-20260526","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/s41598-024-52078-4","article-title":"Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: a multicentric, retrospective cohort study.","volume":"14","author":"Yi","year":"2024","journal-title":"Sci Rep"},{"key":"R20-20260526","doi-asserted-by":"crossref","first-page":"132338","DOI":"10.1016\/j.ijcard.2024.132338","article-title":"Preadmission metformin use increased the incidence of hyperlactatemia at admission and 30-day in-hospital mortality among T2D patients with heart disease at high risk of hypoxia.","volume":"412","author":"Zhang","year":"2024","journal-title":"Int J Cardiol"},{"key":"R21-20260526","doi-asserted-by":"crossref","first-page":"107879","DOI":"10.1016\/j.diabres.2019.107879","article-title":"Metformin lactic acidosis: should we still be afraid?","volume":"157","author":"Salvatore","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"R22-20260526","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/ph13090234","article-title":"Metformin: a potential therapeutic tool for rheumatologists.","volume":"13","author":"Salvatore","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"R23-20260526","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2337\/dc14-0500","article-title":"Metformin and cancer: mounting evidence against an association.","volume":"37","author":"Suissa","year":"2014","journal-title":"Diabetes Care"},{"key":"R24-20260526","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3233\/JAD-180263","article-title":"Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis.","volume":"65","author":"Campbell","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"R25-20260526","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","article-title":"Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.","volume":"13","author":"Lamanna","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R26-20260526","doi-asserted-by":"crossref","first-page":"n1091","DOI":"10.1136\/bmj.n1091","article-title":"SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"R27-20260526","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3121\/cmr.2022.1759","article-title":"Renal complications after percutaneous coronary interventions on concurrent metformin therapy: a systematic review with meta-analysis.","volume":"21","author":"Sakellariou","year":"2023","journal-title":"Clin Med Res"},{"key":"R28-20260526","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1148\/radiol.09090690","article-title":"Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin.","volume":"254","author":"Goergen","year":"2010","journal-title":"Radiology"},{"key":"R29-20260526","first-page":"1829","article-title":"Metformin and contrast media \u2013 increased risk of lactic acidosis?.","volume":"121","author":"Kl\u00f8w","year":"2001","journal-title":"Tidsskr Nor Laegeforen"},{"key":"R30-20260526","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes.","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol Metab Syndr"},{"key":"R31-20260526","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nbt.3623","article-title":"Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data.","volume":"34","author":"Sarangdhar","year":"2016","journal-title":"Nat Biotechnol"},{"key":"R32-20260526","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3390\/ph17030395","article-title":"Digital technology applications in the management of adverse drug reactions: bibliometric analysis.","volume":"17","author":"Litvinova","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"R33-20260526","doi-asserted-by":"crossref","first-page":"104000","DOI":"10.1016\/j.jbi.2022.104000","article-title":"Medication recommendation and lab test imputation via graph convolutional networks.","volume":"127","author":"Mao","year":"2022","journal-title":"J Biomed Inform"},{"key":"R34-20260526","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/dme.13040","article-title":"Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes.","volume":"33","author":"Dujic","year":"2016","journal-title":"Diabet Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:27:15Z","timestamp":1779805635000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":34,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045007","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"2025-03-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}